Identifying and Treating Those at Risk: Disparities in Rapid Relapse Among TNBC Patients in the National Cancer Database.
Health disparities
Social determinants of health
Triple negative breast cancer
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
13 Jun 2024
13 Jun 2024
Historique:
received:
10
01
2024
accepted:
09
05
2024
medline:
14
6
2024
pubmed:
14
6
2024
entrez:
13
6
2024
Statut:
aheadofprint
Résumé
This study was designed to characterize features of rapid relapse TNBC (rrTNBC), an aggressive, poor prognosis breast cancer subset using the National Cancer Database (NCDB). Patients diagnosed with TNBC between 2010 and 2019 within NCDB were included in analyses. rrTNBC was defined as all-cause mortality ≤24 months from diagnosis. Patient demographic, tumor, and treatment association with rrTNBC were evaluated in univariate, bivariate analyses, and multiple logistic regression models. Two-part models are used to compare receipt of treatment (i.e., receipt of both chemotherapy and breast surgery) versus not in its relationship with rrTNBC. Overall, 14.5% of patients were categorized as rrTNBC. Age older than 75 years (-41.3%), Black race (-1.4%), Medicare (-2.6%), and Charlson-Deyo score ≥2 (-4.9%) were associated with a lower probability of receiving both chemotherapy and breast surgery. Not receiving both treatments (vs. receiving both chemotherapy and breast surgery) was associated with a two-to-three-fold higher probability of rrTNBC among patients aged older than 75 years (16.6% vs. 6%), having Medicare (3.6% vs. 1.6%), and Charlson-Deyo score ≥2 (16.6% vs. 5.9%). Age, insurance, and comorbidity were related to a lower likelihood of treatment; yet receiving treatment reduced the risk of rrTNBC threefold for each. These findings might be valuable to inform clinical care delivery, as well as future research that examines treatment protocols among diverse patients.
Identifiants
pubmed: 38872045
doi: 10.1245/s10434-024-15507-2
pii: 10.1245/s10434-024-15507-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938–48. https://doi.org/10.1056/NEJMra1001389 .
doi: 10.1056/NEJMra1001389
pubmed: 21067385
Howlader N, Cronin KA, Kurian AW, Andridge R. Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomark Prevent. 2018;27(6):619–26. https://doi.org/10.1158/1055-9965.Epi-17-0627 .
doi: 10.1158/1055-9965.Epi-17-0627
Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. Cancer. 2007;109(9):1721–8. https://doi.org/10.1002/cncr.22618 .
doi: 10.1002/cncr.22618
pubmed: 17387718
Program SEER. Cancer stat facts: Female breast cancer subtypes. National Cancer Institute. https://seer.cancer.gov/statfacts/html/breast-subtypes.html
Yin L, Duan J-J, Bian X-W, Yu S. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22(1):61. https://doi.org/10.1186/s13058-020-01296-5 .
doi: 10.1186/s13058-020-01296-5
pubmed: 32517735
pmcid: 7285581
Zhang Y, Asad S, Weber Z, et al. Genomic features of rapid versus late relapse in triple negative breast cancer. BMC Cancer. 2021;21(1):568. https://doi.org/10.1186/s12885-021-08320-7 .
doi: 10.1186/s12885-021-08320-7
pubmed: 34006255
pmcid: 8130400
Won KA, Spruck C. Triple-negative breast cancer therapy: Current and future perspectives (Review). Int J Oncol. 2020;57(6):1245–61. https://doi.org/10.3892/ijo.2020.5135 .
doi: 10.3892/ijo.2020.5135
pubmed: 33174058
pmcid: 7646583
Obeng-Gyasi S, Asad S, Fisher JL, Rahurkar S, Stover DG. Socioeconomic and surgical disparities are associated with rapid relapse in patients with triple negative breast cancer. Ann Surg Oncol. 2021;28(11):6500–9.
doi: 10.1245/s10434-021-09688-3
pubmed: 33586064
pmcid: 9143975
Asad S, Barcenas CH, Bleicher RJ, et al. Sociodemographic factors associated with rapid relapse in triple-negative breast cancer: A multi-institution study. J Natl Compr Canc Netw. 2021;19(7):797–804. https://doi.org/10.6004/jnccn.2020.7659 .
doi: 10.6004/jnccn.2020.7659
pubmed: 33691275
pmcid: 8564718
National Cancer I. Overview of the SEER Program. U.S. Department of Health and Human Services. https://seer.cancer.gov/about/overview.html#:~:text=About%20SEER,-SEER%20Program%20Overview&text=SEER%20currently%20collects%20and%20publishes,percent%20of%20the%20U.S.%20population .
Mallin K, Browner A, Palis B, et al. Incident cases captured in the National Cancer Database compared with those in US Population Based Central Cancer Registries in 2012–2014. Ann Surg Oncol. 2019;26(6):1604–12. https://doi.org/10.1245/s10434-019-07213-1 .
doi: 10.1245/s10434-019-07213-1
pubmed: 30737668
National Cancer Database Participant User File 2019 Data Dictionary. 2021/11// 2021.
Kittles RA, Weiss KM. Race, ancestry, and genes: Implications for defining disease risk. Ann Rev Genom Human Genetics. 2003;4(1):33–67. https://doi.org/10.1146/annurev.genom.4.070802.110356 .
doi: 10.1146/annurev.genom.4.070802.110356
Axelsson CK, Mouridsen HT, Zedeler K. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer. 1992;28(8–9):1415–8. https://doi.org/10.1016/0959-8049(92)90534-9 .
doi: 10.1016/0959-8049(92)90534-9
Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer. Cancer. 2008;113(10):2638–45. https://doi.org/10.1002/cncr.23930 .
doi: 10.1002/cncr.23930
pubmed: 18833576
Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429–34. https://doi.org/10.1158/1078-0432.CCR-06-3045 .
doi: 10.1158/1078-0432.CCR-06-3045
pubmed: 17671126
van Roozendaal LM, Smit LHM, Duijsens GHNM, et al. Risk of regional recurrence in triple-negative breast cancer patients: a Dutch cohort study. Breast Cancer Res Treat. 2016;156(3):465–72. https://doi.org/10.1007/s10549-016-3757-4 .
doi: 10.1007/s10549-016-3757-4
pubmed: 27013474
pmcid: 4837212
Ghosh J, Agarwal S, Ganguly S, et al. Patterns of recurrence in triple-negative breast cancer patients (automated IHC): An Indian tertiary care center data. J Clin Oncol. 2018;36(15 suppl):131288. https://doi.org/10.1200/JCO.2018.36.15_suppl.e13128 .
doi: 10.1200/JCO.2018.36.15_suppl.e13128
Davies HT, Crombie IK, Tavakoli M. When can odds ratios mislead? BMJ. 1998;316(7136):989–91. https://doi.org/10.1136/bmj.316.7136.989 .
doi: 10.1136/bmj.316.7136.989
pubmed: 9550961
pmcid: 1112884
Tajeu GS, Sen B, Allison DB, Menachemi N. Misuse of odds ratios in obesity literature: an empirical analysis of published studies. Obesity (Silver Spring). 2012;20(8):1726–31. https://doi.org/10.1038/oby.2012.71 .
doi: 10.1038/oby.2012.71
pubmed: 22436842
pmcid: 3399983
Norton EC, Dowd BE, Maciejewski ML. Marginal effects—Quantifying the effect of changes in risk factors in logistic regression models. JAMA. 2019;321(13):1304–5. https://doi.org/10.1001/jama.2019.1954 .
doi: 10.1001/jama.2019.1954
pubmed: 30848814
Garfield R, Orgera K, Damico A. The Uninsured and the ACA: A Primer—Key Facts about Health Insurance and the Uninsured amidst Changes to the Affordable Care Act: How does lack of insurance affect access to care? 2019. Accessed 2023/04/05/. https://www.kff.org/report-section/the-uninsured-and-the-aca-a-primer-key-facts-about-health-insurance-and-the-uninsured-amidst-changes-to-the-affordable-care-act-how-does-lack-of-insurance-affect-access-to-care/
Halpern MT, Bian J, Ward EM, Schrag NM, Chen AY. Insurance status and stage of cancer at diagnosis among women with breast cancer. Cancer. 2007;110(2):403–11. https://doi.org/10.1002/cncr.22786 .
doi: 10.1002/cncr.22786
pubmed: 17562557
Obeng-Gyasi S, Timsina L, Bhattacharyya O, Fisher CS, Haggstrom DA. Breast cancer presentation, surgical management and mortality across the rural–Urban Continuum in the National Cancer Database. Ann Surg Oncol. 2020;27(6):1805–15. https://doi.org/10.1245/s10434-020-08376-y .
doi: 10.1245/s10434-020-08376-y
pubmed: 32206955
Obeng-Gyasi S, Timsina L, Miller KD, Ludwig KK, Fisher CS, Haggstrom DA. The implications of insurance status on presentation, surgical management, and mortality among nonmetastatic breast cancer patients in Indiana. Surgery. 2018;164(6):1366–71. https://doi.org/10.1016/j.surg.2018.07.012 .
doi: 10.1016/j.surg.2018.07.012
pubmed: 30170816
Gong G, Phillips SG, Hudson C, Curti D, Philips BU. Higher US rural mortality rates linked to socioeconomic status, physician shortages, and lack of health insurance. Health Aff (Millwood). 2019;38(12):2003–10. https://doi.org/10.1377/hlthaff.2019.00722 .
doi: 10.1377/hlthaff.2019.00722
pubmed: 31794316
Casey MM, Thiede Call K, Klingner JM. Are rural residents less likely to obtain recommended preventive healthcare services? Am J Prevent Med. 2001;21(3):182–8. https://doi.org/10.1016/S0749-3797(01)00349-X .
doi: 10.1016/S0749-3797(01)00349-X
Association of American Medical C. Health disparities affect millions in rural U.S. communities AAMC. 2017.
Cox K, Tamir C. Black Americans' identity and connection to community Pew Research Center. 2022.
Bilimoria KY, Bentrem DJ, Stewart AK, Winchester DP, Ko CY. Comparison of commission on cancer-approved and -nonapproved hospitals in the United States: Implications for studies that use the National Cancer Data Base. J Clin Oncol. 2009;27(25):4177–81. https://doi.org/10.1200/jco.2008.21.7018 .
doi: 10.1200/jco.2008.21.7018
pubmed: 19636004
Kim G, Pastoriza JM, Qin J, et al. Racial disparity in distant recurrence-free survival in patients with localized breast cancer: A pooled analysis of National Surgical Adjuvant Breast and Bowel Project trials. Cancer. 2022;128(14):2728–35. https://doi.org/10.1002/cncr.34241 .
doi: 10.1002/cncr.34241
pubmed: 35578919
Parise CA, Caggiano V. The influence of comorbidity on treatment and survival of triple-negative breast cancer. Breast J. 2020;26(9):1729–35. https://doi.org/10.1111/tbj.13924 .
doi: 10.1111/tbj.13924
pubmed: 32488903
Muss HB, Woolf S, Berry D, et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA. 2005;293(9):1073–81. https://doi.org/10.1001/jama.293.9.1073 .
doi: 10.1001/jama.293.9.1073
pubmed: 15741529
Freedman RA, Keating NL, Lin NU, et al. Breast cancer-specific survival by age: Worse outcomes for the oldest patients. Cancer. 2018;124(10):2184–91. https://doi.org/10.1002/cncr.31308 .
doi: 10.1002/cncr.31308
pubmed: 29499074
Wan S, Jubelirer S. Geographic access and age-related variation in chemotherapy use in elderly with metastatic breast cancer. Breast Cancer Res Treat. 2015;149(1):199–209. https://doi.org/10.1007/s10549-014-3220-3 .
doi: 10.1007/s10549-014-3220-3
pubmed: 25472915
Edwards MJ, Campbell ID, Lawrenson RA, Kuper-Hommel MJ. Influence of comorbidity on chemotherapy use for early breast cancer: Systematic review and meta-analysis. Breast Cancer Res Treat. 2017;165(1):17–39. https://doi.org/10.1007/s10549-017-4295-4 .
doi: 10.1007/s10549-017-4295-4
pubmed: 28528451